THE TAPE
FMC · Chemicals & Allied Products · $813.6M

FMC Corporation

$5.23▲ +0.38%
Last close
Relative strength
2RS
of 99, against every stock▲ +1 on the month
Turning up
Caution
−49.9%
six months against Chemicals & Allied Products
52-week range
−71.4%
from the high
$4.37$18.29
Setup
On no screen
No base, flag or squeeze in place tonight. What is and is not there
No report date on the calendar.
Growth WEAKProof PENDING
Quarter to Sep 30, revenue −81% on a year ago
Why it is on no screen

FMC is off the screens on 3 checks.

A base has formed23.8 weeks, from 4.37 to 13.98.
Long enough to count23.8 weeks against 3 needed.
Shallow enough68.7% deep against 35% allowed.
Close to its pivot-62.6% from the pivot; listed down to -20%.
Relative strengthRS 2 against 70 needed.

Measured against the base-and-breakout thresholds. The other screens use their own numbers, so a name can miss here and still be a fair-looking chart.

Draw
9-dayabout two weeks21-dayabout a month50-dayabout a quarter200-dayabout a year
Support and resistance

No price has been tested three times in the last 120 sessions: it has not spent long enough in one range to form a level.

The read

FMC Corporation is not on any of the screens right now. Its relative strength rating is 2, and it sits in Chemicals & Allied Products.

Against its industry
CautionBehind its industry over all three, in an industry that is not ahead of the S&P 500.
One month against its industry
-8.2%
Three months against its industry
-42.0%
Six months against its industry
-49.9%

Read against an equal-weighted index of Chemicals & Allied Products, which is -23.1% against the S&P 500 over six months Not aligned.

Peers
Same theme
No themes — common and fine.
Catalyst roadmap

Nothing dated in the next three months that we can ingest automatically.

How it moves on earnings

On average 20.2% either way across its last 8 reports.

Checking your subscription…

Close before the report day to close after it, so it holds whether the company reported before the open or after the close.

The business
Revenue
$2.8B
-80.5% year on year
Operating margin
-97.0%
gross 22.0%
Net margin
-151.2%
Free cash flow
—
Price to sales
0.29×
Price to earnings
—
not meaningful on a loss

Twelve months to Sep 30, 2026, the four latest quarters in the company’s SEC filings, with the fiscal fourth quarter worked out from the annual report. Revenue growth is the latest quarter against the same quarter a year earlier.

The latest quarter, read by fixed rules · reported Oct 29
Key takeaway
A mixed quarter: the numbers do not agree.
Revenue
$105.9M
-87.8% QoQ · -80.5% YoY
Gross margin
-379.2%
-418.7 pts QoQ
Net income
−$2.1B
Loss
Free cash flow
—

What the numbers say

  • Weak: Revenue -80.5% year over year, -87.8% on the quarter
  • Weak: Gross margin -379.2%, -418.7 points on the quarter
  • Weak: Net loss $2.07B, wider than $187M last quarter
  • Weak: Share count +6.3% in a year: dilution
  • Weak: Net debt $3.23B · cash $736M
Revenue by quarter
Net income
shares +6.3% in a year · net debt $3.2B

What is not obvious

  • Margin quality: depreciation and amortisation $41M is 39% of revenue; gross margin -379.2% reads -417.8% if it is charged there
  • Weak: Interest $74M a quarter against an operating loss: the debt is carried by the balance sheet, not operations

The desk’s own read

Flagged as drifting up since the report

Final read
Growth: WEAK · Economic proof: PENDING
Key question: What turns the cash flow positive?
The next test is revenue growth: revenue -80.5% year over year, -87.8% on the quarter.

From the company’s 10-Q and 10-K filings, by Market Desk’s rules. Every line, the takeaway and the final read are fixed rules on the filed numbers; nothing reads the press release, and none of it enters a screen or a rating. Every recent reporter.

Tracked funds

Held by 2 of 46 tracked funds at the end of Q3 2026.

Last quarter: 2 trimmed.

Checking your subscription…

From 13F filings, which show long stock only and arrive up to 45 days after the quarter. The broad quant funds are left out.

Flagged by the market sweep
GappedTape · 2026-11-13
-10.4%
After this signal, stocks have lagged random stocks by 0.9% over the next three sessions (18,291 cases over 56 nights). Against their own sector they have lagged by 1.2%.
GappedTape · 2026-11-07
-7.2%
After this signal, stocks have lagged random stocks by 0.9% over the next three sessions (18,291 cases over 56 nights). Against their own sector they have lagged by 1.2%.
GappedTape · 2026-11-06
-5.5%
After this signal, stocks have lagged random stocks by 0.9% over the next three sessions (18,291 cases over 56 nights). Against their own sector they have lagged by 1.2%.
GappedTape · 2026-11-05
+5.4%
After this signal, stocks have lagged random stocks by 0.9% over the next three sessions (18,291 cases over 56 nights). Against their own sector they have lagged by 1.2%.
GappedTape · 2026-11-04
-6.3%
After this signal, stocks have lagged random stocks by 0.9% over the next three sessions (18,291 cases over 56 nights). Against their own sector they have lagged by 1.2%.
GappedTape · 2026-10-31
+30.5%
After this signal, stocks have lagged random stocks by 0.9% over the next three sessions (18,291 cases over 56 nights). Against their own sector they have lagged by 1.2%.
Moved 5%+ up on earningsTape · 2026-10-31
+30.5% on earnings 2026-10-29
No measurable effect: stocks behave like random ones over the next three sessions (604 cases over 42 nights).
Reported resultsFiling · 2026-10-30
2.02
No measurable effect: stocks behave like random ones over the next three sessions (2,340 cases over 54 nights).

From a separate overnight market sweep, not from the screens on this site. What it flagged, not what it means. The track record is the sweep's own, measured against random stocks over the last 90 days.

In the news
Insiders

No Form 4 filings read for this company in the last six months. That can mean nobody filed, or that this name has not been on a screen long enough for us to have fetched them.

What analysts expect
Strong buy0
Buy6
Hold9
Sell1
Strong sell1

These are analysts’ estimates, not ours, and not a projection this site endorses. They are published here because what the sell side expects is itself a fact about the market.

Checking your subscription…

Gamma concentration

No option open interest for this company. Most listed names have no options at all, and we only read chains for names carrying a dated event, so this is a normal reading rather than a fault.

X-ray

No completed base to compare this one with yet.

A screening and market-analytics tool. Not investment advice. We are not a registered investment adviser. A stock on a screen matches a shape; that is not a prediction. Prices are end-of-day, not live.

What that means, in full
FMC Corporation (FMC) — The Tape